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As our knowledge and understanding of organisms of the
Burkholderia cepacia complex (Bcc) progresses, further species
have been recognised that are of (as yet) uncertain clinical
significance [1]. With this letter we report on three patients
attending our adult CF unit who are all chronically infected with
Burkholderia latens, a species of Bcc that was only described in
2008, and for which there is a paucity of clinical outcome data.
Moreover, all three patients have lived within a narrow
geographical radius, which raises the possibilities of either a
common environmental source or transmissibility of B. latens
between patients. It is too early to infer the longer term
consequences of B. latens infection, but so far none of the patients
appear to have suffered a deterioration attributable to the infection.
1. Background
Organisms of the Bcc are now well recognised as important
pathogens in the CF lung, though the clinical effect varies
markedly between patients [2]. Polyphasic taxonomic analyses
have revealed that the Bcc comprises 17 different species, or
genomovars. All Bcc are found in a wide variety of environments
and most have also been isolated from the sputum of CF patients.
The most prevalent species are B. multivorans (genomovar II),
and B. cenocepacia (genomovar III), which account for 90% of
infections in CF [3]. Almost half of the newer species have been
described in the last 2–3 years with five novel species of Bcc
described by Vanlaere et al. in 2008, all of which had also been
found in the sputum of CF patients [1]. One of these, B. latens,
was named after the Latin for concealed, because the taxonomic
status of this species had remained unclear for a long time.
To date, there have been no other reports of B. latens
infection, and no data on the clinical consequences of infection.
2. Patient details
1. Patient A is a 23 year old female on the lung transplant
waiting list (FEV1 23% predicted). She was first infected by
an unidentified organism of the Bcc over 10 years ago.
2. Patient B is a 23 year old male (FEV1 55% predicted) who
was also chronically infected with the same strain of Bcc
since childhood. He lives only 1 mile from patient A and
previously shared a bus to school.1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.01.001In both cases, the organism was eventually identified as
B. latens in 2009.
3. Patient C is a 26 year old female (FEV1 37% predicted) who
was first infected with B. latens in May 2008. She now lives
in a separate town, over 20 miles away, but had lived in the
same town as patients A and B until 2 years previously, and
her parents still live there. She had also attended the same CF
unit as a child, though had transferred care to the regional
adult centre 9 years prior to the first isolation of B. latens.3. Microbiology
All B. latens isolates were confirmed by recA gene sequence
cluster analysis [4] at the national reference laboratory and all
shared identical recA sequences with each other, and with
LMG24064T, over the region compared (nt 75 to 971 of
GenBank accession number AF143788). Pulsed-field gel electro-
phoresis (PFGE) profiles showed greater than 90% similarity
based on an unweighted pair group method with arithmetic
averages (UPGMA) clustering [5]. Multiple isolates have been
obtained from each of the 3 patients, and they are all considered
chronically infected.
Formal eradication has not been attempted, but all three
patients have receivedmultiple courses of intravenous antibiotics.
B. latens cultures from all patients have been consistently resistant
on standard microbiological testing to ciprofloxacin, meropenem,
colistin and tobramycin. Isolates have usually been sensitive to
ceftazidime, tazocin and minocycline, with less consistent
sensitivity to temocillin and aztreonam. A single B. latens isolate
from patient A showed resistance to all routinely tested
antibiotics. Antibiotic synergy testing has not been performed.
4. Clinical impact
Over the preceding 3 years, annual decline in FEV1 has been
6.5% for patient A and 4.5% for patient B, though in both cases
this clinical deterioration has not been attributed to Bcc
infection. Annual decline in FEV1 for patient C was 1.5%,
and there was no significant change in spirometry (FEV1 and
FVC), rate of decline in spirometry or weight following
isolation of B. latens. There have been no cases of cepacia
syndrome sepsis in any of the three patients.
5. Clustering of cases
All three cases are in some way geographically linked to the
same town, and have previously lived within a radius ofd by Elsevier B.V. All rights reserved.
292 Letter to the Editor2.5 miles (4 km). There is no indication that patient C was
infected at the adult CF unit— she attends clinic on a different
day to the other two and has never been admitted at the same
time as them. Although they do not mix socially, the first two
cases are known to have been in close proximity, and patient to
patient transmission between these two cases is possible.
Inadvertent community contact between patient C and either of
the other two cases cannot be excluded.
Laboratory contamination is ruled out by the presence of
repeated isolates.
6. Summary
This report is the first to provide clinical outcome data on
patients chronically infected with B. latens. There do not
appear, in this limited sample, to have been any short term
adverse effects on lung health, though accurate data on this
relate principally to one subject (patient C). Two patients have
been chronically infected for some years, and have had greater
than average falls in lung function, though in both cases
B. latens has not been held to be responsible.
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